Disability Hospital Confinement Rider

A Disability Hospital Confinement Rider is an optional add-on to a disability insurance policy that provides additional benefits to the insured in the event that they are hospitalized due to a covered illness or injury.  

Here are some key features of a Disability Hospital Confinement Rider:

  • Definition of hospital confinement: The rider specifies what constitutes a hospital confinement, such as an overnight stay in a hospital or other medical facility.

  • Benefit amount: The rider provides a specified benefit amount, which is typically paid on a daily basis, to the insured for each day they are confined in a hospital due to a covered disability.

  • Waiting period: There may be a waiting period before benefits are paid, similar to an elimination period in a disability insurance policy.

  • Benefit duration: The rider may have a maximum benefit period, which limits the total amount of benefits that can be paid out for hospital confinement.

  • Additional premium: The rider typically requires an additional premium to be paid by the insured to add the coverage to their disability insurance policy.

For example, if an insured person has a disability insurance policy with a Disability Hospital Confinement Rider and they are hospitalized due to a covered illness or injury, they may receive a daily benefit payment for each day they are confined in the hospital. The benefit amount and duration will depend on the terms of the rider and the underlying disability insurance policy.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.